After decades of unfulfilled potential, the commercial reality of gene therapies is rapidly taking shape. However, the leading drug developer organizations in this field are telling us that developing effective analytical strategies is a major bottleneck for them and that they have little visibility into which contract service providers and technology providers have the analytical experience and specific technologies to meet their demands.
150+ Analytical, CMC, Process Development & QC leaders from the fields leading companies will unite in May at the 3rd Annual Gene Therapy Analytical Development Europe. From extensive research with these organisations, we are aware that they are all actively seeking to collaborate with companies that can help them solve their analytical challenges holding back progress to market.
If you are a contract service or technology provider with the analytical experience and specific technologies to meet these exploding markets’ demands, then Gene Therapy Analytical Development Europe will provide a platform for you to showcase your solutions to a niche audience of analytical experts from the leading gene therapy developers.
We have a limited number of partnership opportunities available, including speaking positions across our agenda. From developing robust potency assays to next-generation sequencing, if you provide analytical services or technologies that would benefit our niche industry audience, then this meeting will provide a unique platform to showcase your solutions, generate new business leads, and source opportunities for partnerships.